With multifocal GIM at repeat EGD (n = 18) | Without multifocal GIM at repeat EGD (n = 63) | |
---|---|---|
Male, n (%) | 6 (33.3%) | 30 (47.6%) |
Age at index EGD, median (IQR) | 58 (55 – 68) | 58 (53 – 64) |
Smoking history, n (%) | ||
Never | 14 (77.8%) | 41 (65.1%) |
Current | 1 (5.6%) | 10 (15.9%) |
Former | 3 (16.7%) | 12 (19.0%) |
History of GERD | 7 (38.9%) | 23 (36.5%) |
History of H. pylori infection | 9 (50.0%) | 20 (31.7%) |
Family history of 1st degree relative with cancer | ||
No family history | 14 (77.8%) | 46 (74.2%) |
Gastric cancer | 0 (0.0%) | 3 (4.8%) |
Non-gastric GI cancer | 1 (5.6%) | 6 (9.7%) |
Other cancer | 3 (16.7%) | 8 (12.9%) |
Hemoglobin at time of index EGD, median (IQR) | 12.7 (9.7 – 13.4) | 12.5 (11.2 – 13.8) |
Recommended interval for repeat EGD for GIM surveillance | ||
No recommendation | 4 (22.2%) | 23 (36.5%) |
< 3 months | 0 (0.0%) | 3 (4.8%) |
3–6 months | 1 (5.6%) | 5 (7.9%) |
1 year | 3 (16.7%) | 14 (22.2%) |
2–3 years | 9 (50.0%) | 19 (30.2%) |
5 years | 1 (5.6%) | 0 (0.0%) |
Location of endoscopic abnormality observed at index EGD | ||
No abnormalities | 2 (11.1%) | 6 (9.8%) |
Antrum | 5 (27.8%) | 28 (45.9%) |
Body | 6 (33.3%) | 19 (31.1%) |
Pylorus | 2 (11.1%) | 4 (6.6%) |
Cardia | 3 (16.7%) | 4 (6.6%) |
Fundus | 4 (22.2%) | 5 (8.2%) |
Generalized | 5 (27.8%) | 13 (21.3%) |
Angularis | 0 (0.0%) | 4 (6.6%) |
Type of endoscopic abnormality observed at index EGD | ||
No abnormalities | 2 (11.1%) | 6 (10.0%) |
Erythema | 5 (27.8%) | 6 (10.0%) |
Nodularity | 0 (0.0%) | 11 (18.3%) |
Erythema and erosions | 3 (16.7%) | 12 (20.0%) |
Atrophic/decreased folds | 3 (16.7%) | 8 (13.3%) |
Ulcer | 3 (16.7%) | 12 (20.0%) |
Polyps | 1 (5.6%) | 9 (15.0%) |
Othera | 4 (22.2%) | 13 (21.6%) |